Participants were randomly allocated ( @:@:@ ratio ) to receive PCV@ in addition to routine immunisations either as a two-dose prime and boost ( @ +@ ) , three-dose prime ( @ +@ ) , or two doses after completion of the initial study phase ( @ +@ ) .